PubRank

Journal of comparative effectiveness research (J Comp Eff Res)

Journal PubWeight™ 130.35‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. 2012 1.91
2 Using observational studies for comparative effectiveness: finding quality with GRACE. 2013 1.41
3 Long-term cost-effectiveness of Oncotype DX(®) versus current clinical practice from a Dutch cost perspective. 2015 1.40
4 Field testing the ENSEMBLE Minimum Dataset: performance of an instrument to address heterogeneity of treatment effects. 2014 1.38
5 Evaluating patient and stakeholder engagement in research: moving from theory to practice. 2015 1.36
6 Comparative effectiveness research and big data: balancing potential with legal and ethical considerations. 2015 1.10
7 Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. 2012 1.04
8 Modernizing the systematic review process to inform comparative effectiveness: tools and methods. 2013 1.02
9 Building useful evidence: changing the clinical research paradigm to account for comparative effectiveness research. 2012 1.01
10 Patient and clinician views on comparative effectiveness research and engagement in research. 2015 0.99
11 Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. 2013 0.99
12 Using health technology assessment for informing coverage decisions in Thailand. 2012 0.97
13 Insights from a conference on implementing comparative effectiveness research through shared decision-making. 2013 0.95
14 Using modeling to inform patient-centered care choices at the end of life. 2013 0.95
15 Comparison of evidence-based interventions on outcomes of hospitalized, cognitively impaired older adults. 2014 0.94
16 Role of practice-based research networks in comparative effectiveness research. 2012 0.94
17 Stakeholder engagement in comparative effectiveness research: how will we measure success? 2012 0.93
18 Principles for planning and conducting comparative effectiveness research. 2012 0.93
19 Engaging hard-to-reach patients in patient-centered outcomes research. 2013 0.91
20 Engaging older adults in their transitional care: what more needs to be done? 2013 0.91
21 Involving the public in systematic reviews: a narrative review of organizational approaches and eight case examples. 2012 0.91
22 How a unique provision in the American Recovery and Reinvestment Act set a foundation for the Patient-Centered Outcomes Research Institute. 2014 0.91
23 Incorporating stakeholder perspectives in developing a translation table framework for comparative effectiveness research. 2012 0.91
24 Which design for which question? An exploration toward a translation table for comparative effectiveness research. 2012 0.91
25 A translation table for patient-centered comparative effectiveness research: guidance to improve the value of research for clinical and health policy decision-making. 2012 0.91
26 Use of community-based participatory research in primary care to improve healthcare outcomes and disparities in care. 2013 0.90
27 Role of electronic health records in comparative effectiveness research. 2013 0.90
28 Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations. 2014 0.89
29 Comparative effectiveness research in chronic obstructive pulmonary disease. 2012 0.89
30 Applications of propensity score methods in observational comparative effectiveness and safety research: where have we come and where should we go? 2013 0.89
31 Using comparative effectiveness research to inform decision-making: is there a role of economic evaluation? 2012 0.89
32 Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction. 2014 0.88
33 Improving the relevance and consistency of outcomes in comparative effectiveness research. 2016 0.88
34 Should criteria for inclusion in cancer clinical trials be expanded? 2015 0.88
35 Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. 2014 0.87
36 A tall order on a tight timeframe: stakeholder perspectives on comparative effectiveness research using electronic clinical data. 2012 0.87
37 Dissemination and implementation of comparative effectiveness evidence: key informant interviews with Clinical and Translational Science Award institutions. 2013 0.87
38 What does US$1.1 billion buy? An investment in the future. 2014 0.87
39 Unresolved tensions in consumer engagement in CER: a US research perspective. 2013 0.86
40 Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals. 2015 0.86
41 The role of private industry in pragmatic comparative effectiveness trials. 2012 0.85
42 Medical devices are different to pharmaceuticals in the Health Technology Assessment process. 2014 0.85
43 Pros and cons of pragmatic clinical trials. 2013 0.85
44 Electronic health records: current and future use. 2014 0.85
45 Using community-based participatory research in patient-centered outcomes research to address health disparities in under-represented communities. 2015 0.84
46 Generic atypical antipsychotic drugs in Belgium: their influence and implications. 2013 0.84
47 Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. 2012 0.84
48 Comparative effectiveness of biologic antirheumatic therapies in rheumatoid arthritis after failure to respond to a first TNF inhibitor. 2012 0.84
49 Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient. 2015 0.84
50 The value of linking hospital discharge and mortality data for comparative effectiveness research. 2013 0.83
Next 50